Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Business & Technology Briefs (09/2007)

Executive Summary

Brief summaries of recent product and company developments in the device industry, including Medtronic's acquisition of Kyphon, Siemens' purchase of Dade, and the FoxHollow/ev3 merger.

You may also be interested in...



In Vitro Diagnostics: Innovation and Integration

Integration is occuring at almost every level of the in vitro diagnostic industry--at the preclinical level to decrease drug development costs and timelines and at the clinical level to better manage diseases. In the lab, there's a demand for new tools to improve speed and efficiency, and new information systems to better integrate disparate data. At the same time, there has been a flurry of integration and consolidation at the market level, with 35 mergers and acquisitions in the last 12 months.

Kyphon Steps Up

A year ago at this time, a sale to another company was the last thing on the minds of senior executives at St. Francis Medical, one of the leading companies in dynamic stabilization. But interest by large spine companies put a halt to the company's plans to go public and led to an auction that was eventually won by Kyphon. Kyphon's acquisition of St. Francis Medical was one of the device industry's biggest deals in 2006--and just what everyone was waiting for.

GE Grabs the Spotlight in IVD

The entry by GE into the core lab business via its acquisition of Abbott's clinical diagnostics businesses follows a similar move by Siemens last year, and suggests IVD may be best suited for generalist industrial giants. While the pricing pressures that have dogged this segment of diagnostics are not likely to abate, existing players--including Abbott--are continuing to develop high-margin molecular diagnostic tests that they expect the new players will want to incorporate into their platforms.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT035104

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel